Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page j9 z- j" F' }
# D7 D9 [3 e& _. G
, h+ @3 F% K6 y8 [4 K
Sub-category:
+ C$ P2 Y' j( t& q, u, o' ~ b, t3 I7 I+ fMolecular Targets % a4 }! n8 s1 L G @7 b. v
, g# f, ~2 Z2 l! L* n- k. K) ?7 l' H9 U. E$ F% D
Category:$ b& [- N0 E& ]7 L1 }3 O0 r9 ~
Tumor Biology ; v$ T7 M1 O9 C+ n4 `& P
0 A' }- f+ v; ]: a4 N5 l
! q H5 ]) y9 n6 c' V, N
Meeting:
: L$ U% J& r8 \2011 ASCO Annual Meeting 3 m3 R8 @4 ^ D) L. l0 ?/ |+ i
& A- a9 q) W; e$ P7 }! R- b
( |/ t/ N# c- U) w9 L3 z
Session Type and Session Title:' e; S$ [) e1 F. s% ?
Poster Discussion Session, Tumor Biology ; X: T0 p4 m7 M( v
+ g+ N+ g* |! c; K
1 K; I* P7 l$ S L* rAbstract No:
/ k* M: C t' I+ u0 i+ H! B$ z! r7 `10517 7 ]+ n* s7 ?# V' r. K% C* T
: w* ?$ d% m8 _ X; P9 @2 g, S* n. H! l# Q+ x+ d' V5 Q( K1 ]
Citation:
$ u o& {6 l8 L8 _3 m6 N* b) J. {J Clin Oncol 29: 2011 (suppl; abstr 10517) - i3 s% o* h! t' I5 c/ \
% e0 T2 n: Y' ~$ j
0 `* w, E% [ L+ L, V1 C; H! j
Author(s):
. |* o1 f1 q- B9 b3 Y9 f O0 p8 J- ~8 sJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
4 i* ?5 f" g1 j" j, r# U" [8 x5 {4 x& v" E- V. z& M# L" A
e' |! J) O# z
- g, V8 X. Q$ LAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings. C" v3 ~0 G& V; p& t2 U
+ X. ?, `: ?/ b: H. O
Abstract Disclosures
; E; j( H8 w' K2 x! Z" x# C3 l- J9 y' R6 W4 W' G) }, S& S6 k* O9 d
Abstract:
) W5 O& X6 q7 x& l
& w( c/ ?) [& V# u9 Q5 \
2 r8 U1 F+ E2 b+ e/ UBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.. @" ]1 [5 K5 t& @) t2 q
, Z7 S6 F; i1 |2 V
- o0 n& }% s/ u# e/ f9 Q |
# R0 ]) L/ m. G. `8 |
显身卡
